Pacira BioSciences (PCRX) Stock Overview
Engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for PCRX from our risk checks.
PCRX Community Fair Values
Create NarrativeSee what 16 others think this stock is worth. Follow their fair value or set your own to get alerts.
Pacira BioSciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$21.36 |
| 52 Week High | US$27.64 |
| 52 Week Low | US$16.00 |
| Beta | 0.41 |
| 1 Month Change | -15.37% |
| 3 Month Change | -1.88% |
| 1 Year Change | 24.33% |
| 3 Year Change | -59.28% |
| 5 Year Change | -59.71% |
| Change since IPO | 204.27% |
Recent News & Updates
Recent updates
Pacira BioSciences: Worth Pondering, Strong Balance Sheet
Jul 29Pacira BioSciences (NASDAQ:PCRX) Seems To Use Debt Quite Sensibly
Jun 11
Pacira BioSciences Remains A 'Buy' For Pain Management With The NOPAIN Act
Apr 09Pacira BioSciences, Inc. (NASDAQ:PCRX) Looks Inexpensive But Perhaps Not Attractive Enough
Apr 07Pacira BioSciences: Back On An Uptrend After Positive Developments
Mar 14Pacira BioSciences (NASDAQ:PCRX) Has A Rock Solid Balance Sheet
Jan 30Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Low P/S No Reason For Excitement
Jan 03Pacira BioSciences: Not Done Yet Despite Devastating Share Price Losses
Nov 25
EXPAREL's Calculated Expansion And Innovative R&D Bolster Market Dominance Amidst Challenges
Expanding EXPAREL utilization in outpatient settings and through GPO partnerships aims to enhance revenue by increasing market penetration and affordability.Pacira BioSciences, Inc. (NASDAQ:PCRX) Not Doing Enough For Some Investors As Its Shares Slump 34%
Sep 06Little Excitement Around Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Revenues As Shares Take 29% Pounding
Jul 23These 4 Measures Indicate That Pacira BioSciences (NASDAQ:PCRX) Is Using Debt Safely
Jun 07Pacira BioSciences, Inc. Just Missed Earnings - But Analysts Have Updated Their Models
May 10Getting In Cheap On Pacira BioSciences, Inc. (NASDAQ:PCRX) Might Be Difficult
May 03Does Pacira BioSciences (NASDAQ:PCRX) Have A Healthy Balance Sheet?
Feb 05Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Low P/S No Reason For Excitement
Jan 05We Think Pacira BioSciences (NASDAQ:PCRX) Can Stay On Top Of Its Debt
Nov 03Is Pacira BioSciences (NASDAQ:PCRX) Using Too Much Debt?
Jul 28Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Intrinsic Value Is Potentially 26% Below Its Share Price
Jul 07Shareholder Returns
| PCRX | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -3.0% | 0.8% | 2.0% |
| 1Y | 24.3% | -3.6% | 18.7% |
Return vs Industry: PCRX exceeded the US Pharmaceuticals industry which returned -3.6% over the past year.
Return vs Market: PCRX exceeded the US Market which returned 18.7% over the past year.
Price Volatility
| PCRX volatility | |
|---|---|
| PCRX Average Weekly Movement | 4.7% |
| Pharmaceuticals Industry Average Movement | 9.4% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PCRX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: PCRX's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 789 | Frank Lee | www.pacira.com |
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis.
Pacira BioSciences, Inc. Fundamentals Summary
| PCRX fundamental statistics | |
|---|---|
| Market cap | US$958.41m |
| Earnings (TTM) | -US$127.46m |
| Revenue (TTM) | US$705.85m |
Is PCRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PCRX income statement (TTM) | |
|---|---|
| Revenue | US$705.85m |
| Cost of Revenue | US$236.42m |
| Gross Profit | US$469.43m |
| Other Expenses | US$596.89m |
| Earnings | -US$127.46m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.84 |
| Gross Margin | 66.51% |
| Net Profit Margin | -18.06% |
| Debt/Equity Ratio | 76.6% |
How did PCRX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/28 22:49 |
| End of Day Share Price | 2025/10/28 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Pacira BioSciences, Inc. is covered by 30 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Anita Dushyanth | Berenberg |
| Gary Nachman | BMO Capital Markets Equity Research |
| Tazeen Ahmad | BofA Global Research |